Compare ROIV & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | MKL |
|---|---|---|
| Founded | 2014 | 1930 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 23.2B |
| IPO Year | 2021 | 1999 |
| Metric | ROIV | MKL |
|---|---|---|
| Price | $38.91 | $1,944.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 7 |
| Target Price | $50.82 | ★ $1,980.17 |
| AVG Volume (30 Days) | ★ 7.1M | 54.0K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 91.90 |
| Revenue | $8,260,000.00 | ★ $15,513,233,000.00 |
| Revenue This Year | $1,870.25 | N/A |
| Revenue Next Year | $271.46 | N/A |
| P/E Ratio | ★ N/A | $21.23 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.96 | $1,704.17 |
| 52 Week High | $42.50 | $2,207.59 |
| Indicator | ROIV | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 57.65 |
| Support Level | $33.11 | $1,918.84 |
| Resistance Level | $42.37 | $2,008.51 |
| Average True Range (ATR) | 1.55 | 33.57 |
| MACD | -0.07 | -4.83 |
| Stochastic Oscillator | 49.40 | 50.35 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Markel's primary business is property-casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.